Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2009-12-02

FDA Approved: SEROQUEL — Supplemental Application (H2-Pharma, LLC)

View source ↗

Summary

The FDA approved a supplemental application for SEROQUEL (quetiapine) submitted by H2-Pharma, LLC, likely involving changes to the drug's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SEROQUEL (QUETIAPINE)

Snippet

SUPPL AP for SEROQUEL (QUETIAPINE)